Key Dates

Related Announcements

• March 6, 2024 - Notice of Participation of the National Institute of Nursing Research (NINR) in NOT-OD-24-038, "Notice of Special Interest: Health Influences of Gender as a Social and Structural Variable". See Notice NOT-NR-24-007
• September 12, 2023 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity). See NOFO PA-23-271.
• September 7, 2023 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30). See NOFO PA-23-261.
• September 7, 2023 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32). See NOFO PA-23-262.
• August 17, 2023 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31). See NOFO PA-23-272.
• August 16, 2023 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30). See NOFO PA-23-260.
• May 10, 2023 - Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional). See NOFO PAR-23-190
• May 10, 2023 - HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional). See NOFO PAR-23-191.
• January 11, 2023 - Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional). See NOFO PAR-23-060.
• January 11, 2023 - Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Option). See NOFO PAR-23-061.
• January 11, 2023 - Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Option). See NOFO PAR-23-062.
• December 5, 2022 - NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional). See NOFO PAR-23-058.
• May 10, 2022 - Dissemination and Implementation Research in Health (R01 Clinical Trial Optional). See NOFO PAR-22-105.
• May 9, 2022 Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed). See NOFO PAR-22-106.
• February 9, 2022 - Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional). See NOFO PAR-22-098.
• February 8, 2022 - Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional). See NOFO PAR-22-097.
• December 13, 2021 - Risk and Protective Factors of Family Health and Family Level Interventions (R01 Clinical Trial Optional). See NOFO PAR-21-358.
• October 12, 2021 - Exploratory Grants in Cancer Control (R21 Clinical Trial Optional). See NOFO PAR-21-341.
• October 5, 2021 - Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed). See NOFO PAR-21-350.
• October 5, 2021 - Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required). See NOFO PAR-21-349
• October 5, 2021 - Risk and Protective Factors of Family Health and Family Level Interventions (R01 Clinical Trial Optional). See NOFO PAR-21-352.
• August 31, 2021 - NCI Mentored Research Scientist Development Award to Promote Diversity (K01 - Clinical Trial Required). See NOFO PAR-21-296.
• August 31, 2021 - NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed). See NOFO PAR-21-295.
• May 11, 2021 - Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders. See NOFO PA-21-180.
• March 12, 2021 - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional). See NOFO PAR-21-190.
• May 12, 2020 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed). See NOFO PA-20-205.
• May 12, 2020 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required). See NOFO PA-20-206.
• May 12, 2020 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed). See NOFO PA-20-203.
• May 12, 2020 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required). See NOFO PA-20-202.
• May 7, 2020 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed). See NOFO PA-20-200.
• May 7, 2020 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed). See NOFO PA-20-195.
• May 7, 2020 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required). See NOFO PA-20-194.
• May 7, 2020 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required). See NOFO PA-20-196.
• May 6, 2020 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed). See NOFO PA-20-190.
• May 6, 2020 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required). See NOFO PA-20-176.
• May 5, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Required). See NOFO PA-20-183.
• May 5, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed). See NOFO PA-20-185.
• May 5, 2020 - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required). See NOFO PA-20-184.

Issued by

Office of Research on Women's Health (ORWH)

Office of AIDS Research (OAR)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Aging (NIA)

National Institute of Allergy and Infectious Diseases (NIAID)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

Fogarty International Center (FIC)

National Cancer Institute (NCI)

National Institute of Nursing Research (NINR) - March 6, 2024 - Participation Added (NOT-NR-24-038)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Sexual and Gender Minority Research Office (SGMRO)

Purpose

The National Institutes of Health (NIH) vision for women’s health is a world in which the influences of sex and gender are rigorously integrated into the health research enterprise. For the purposes of this Notice, sex refers to a set of biological variables, including anatomy, physiology, genetics, and hormones. For the purposes of this Notice, gender refers to a set of social and structural variables that encompass gender identity and expression, gender roles and norms, gender relations, and gender power systems (e.g., structural sexism).

Sex-linked biology and gender-related factors can act independently or interactively to influence health. As a social, cultural, and structural construct, gender encompasses multiple domains. Many other social variables including race, ethnicity, disability, sexual orientation, socioeconomic status, and education intersect with gender to impact health and disease in unique ways. Intersectional frameworks enable consideration of how these socially determined categories overlap and interact to create disparate and inequitable outcomes for individuals and communities.

The NIH Office of Research on Women’s Health (ORWH) and our Institute, Center, and Office (ICO) partners are issuing this Notice to highlight interest in receiving research and training grant applications focused on health impacts of gender-related social and structural variables. For this Notice, relevant domains of gender are gender roles and norms, gender relations, gender equity/inequity, gender equality/inequality, gender-related power dynamics, and structural sexism. Applications can consider one or more domains as they relate to health.

For consideration under this NOSI, applications should have a clear and central focus on social and/or structural domains of gender as demonstrated through a primary aim of EITHER (1) elucidating modifiable factors in gender-related health disparities OR (2) developing, testing, or implementing social or structural interventions to mitigate gender-related health disparities OR (3) investigating the interactions between multiple social and structural domains of gender (e.g., gender roles and gender inequity; power and gender relations). In each of these potential areas of focus, intersectional approaches to gender-related social and structural variables are strongly encouraged.

Topics of particular interest are:

• Community-led interventions to address gender-related health disparities
• Development or testing innovative, intersectional approaches to addressing gender-related health disparities
• Projects to enhance understanding of health disparities based in structural sexism, gender norms, relational power dynamics, and/or gender inequities
• Projects to develop, test, implement and/or evaluate interventions aimed at mitigating health disparities based in structural sexism, gender norms, relational power dynamics, and gender inequities. Interventions can target one or multiple levels of gender-related variables
• Gendered influences on prevention, treatment, and outcomes of female-specific conditions and diseases more common in women (e.g., fibroids, autoimmune diseases)
• Research that evaluates one or more health prevention and treatment outcomes in light of legal and policy issues at the intersections of public health surveillance, care delivery, and social and structural domains of gender

Office of Research on Women’s Health (ORWH)

ORWH is part of the Office of the Director, NIH, and works with the 27 NIH Institutes and Centers to advance rigorous research of relevance to the health of women. ORWH does not award grants but co-funds women’s health-related applications and research projects that have received an award from one of the participating NIH Institutes and Centers listed in the announcement. Applications seeking ORWH co-funding, in response to this Notice, should ensure that the proposed work is aligned with at least one goal and objective outlined in the Trans-NIH Strategic Plan for Women’s Health Research.

National Institute on Aging (NIA)

NIA is interested in supporting research focused on health influences of gender as a social and structural variable in studies that align with the goals outlined in the National Institute on Aging’s Strategic Directions for Research, 2020-2025. Applicants are particularly encouraged to propose research that is guided by the NIA Health Disparities Research Framework, on and with members of NIA’s Priority Populations. Applications proposing to develop and test behavioral interventions are expected to apply the NIH Stage Model for Behavioral Intervention Development framework in the description of the proposed study aims and research activities.

NIA will consider meritorious applications that fall within the Institute’s pay line. Projects focused on examining gender-related social and structural variables in the context of Alzheimer's disease and Alzheimer's disease-related dementias should be submitted in response to NOT-AG-21-050: Notice of Special Interest (NOSI): Sex and Gender Differences in Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD).

National Institute of Neurological Disorders and Stroke (NINDS)

The National Institute of Neurological Disorders and Stroke (NINDS) is interested in applications within the NINDS mission and supports clinical and implementation research focused on identifying, monitoring, and targeting biological, environmental, social, community, structural, and healthcare system factors that lead to or are associated with disparities (or inequities) in neurological diseases and care across the lifespan (NINDS Disorders Index: https://www.ninds.nih.gov/health-information/disorders). NINDS is particularly interested in mission-relevant clinical studies that address the intersection between gender and NIH-designated populations who experience health disparities (HDPs), including, but not limited to:

• Projects to enhance understanding of neurological health disparities based in structural sexism, gender norms, relational power dynamics, gender inequities, and/or intersectional oppression.
• Projects that identify and measure specific modifiable social determinants of health that contribute to gender-based neurological health disparities among NIH-designated HDPs.
• Projects to identify strategies to address structural sexism, organizational practices, policies and other social, cultural, and contextual factors that lead to disparate gender-based neurological health outcomes among NIH-designated HDPs.

Applicants are encouraged to utilize the NINDS SDOH framework for addressing health inequities and incorporate community engagement strategies into their clinical study designs. Many core principles of community engagement (trust, inclusivity, culturally-centered, etc.) are outlined in the National Academy of Medicine’s Advancing Health Equity and Systems Transformation through Community Engagement.

Please refer to https://www.ninds.nih.gov/Funding/Find-Funding-Opportunities and/or contact appropriate NINDS program staff to find the appropriate NINDS-specific NOFO for other types of clinical trials. The NINDS encourages the use of common data elements (see NINDS CDE Project: https://www.commondataelements.ninds.nih.gov/). A letter of intent and communication with appropriate NINDS program staff prior to submission of an application is strongly encouraged.

National Institute of Mental Health (NIMH)

NIMH will only accept HIV/AIDS applications. Mental health applications that do not study HIV/ AIDS are non-responsive and will not be reviewed.

NIMH Division of AIDS Research is interested in the development and testing of interventions to address gender-related influences on HIV prevention and treatment outcomes. Applicants are encouraged to consider the ways in which gender intersects with other social variables to impact HIV-related health outcomes. Areas of specific interest include gender transformative interventions to address gender norms, economic empowerment interventions for people that are economically disadvantaged based on their gender, and interventions addressing gender-based violence, with a primary focus on improving HIV prevention and treatment outcomes.

National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting projects that explore the social and structural domains of gender that are relevant to domestic and international collaborative research related to components of NIAID’s scientific mission. Areas of programmatic interest include the following:

• HIV- and STI-related research - gender-related social and structural variables that influence access, uptake, and adherence to biomedical primary HIV and STI prevention strategies (e.g. antiretrovirals/ARVs, such as long-acting agents, for pre-exposure prophylaxis/PrEP; ARVs for post-exposure prophylaxis/PEP, multipurpose prevention technologies (MPT), antimicrobials for pre- and post-exposure prophylaxis), strategies for suppression and control of HIV to prevent transmission, concomitant STIs, other co-infections, and infectious comorbidities in adults and/or adolescents, including pregnant people.
• Analyses of social determinants of health including race, ethnicity, disability, socioeconomic status, and education that, when combined with social and structural domains of gender, demonstrate a collective influence on HIV- and STI-related prevention and treatment outcome(s).

The National Institute on Drug Abuse (NIDA)

NIDA is interested in research that will address social and structural determinants of health among people at risk for substance use and who use addictive substances. A topic of particular interest is research that implement evidence-based strategies to address intersectional stigma, including substance use- and HIV-related stigma and power dynamics/imbalances, particularly among populations that experience a disproportionate impact of substance use (e.g., women of color, sexual/gender minorities, justice-involved women) to enhance substance use prevention and service delivery efforts.

NIDA seeks to support research that address factors that impede and facilitate the delivery of gender-tailored, high-quality, effective addiction treatment services at one or more levels (e.g., individual, patient-provider, family, organizational, community, or system). Of particular interest is research that develop, test, and implement gender-tailored interventions that facilitate the referral, receipt, and retention in substance use treatment/services among non-Hispanic black/African American women and other women of color with substance use disorder.

NIDA strongly encourages applicants to: 1) engage and include the perspectives of relevant practitioners and stakeholders (e.g., individuals with lived expertise/experience) in study conceptualization, design, execution, interpretation, and dissemination of findings; 2) consider the potential adaptability, scalability, equity, and sustainability of the proposed evidence-based interventions; and 3) ensure translation and dissemination of study findings and related resources to key audiences best positioned to influence change in practice.

NIDA strongly encourages (when applicable) applications proposing research with human subject samples to use NIDA funded and co-funded data and specimen resources openly available for investigators. Examples include: PhenX Toolkit (https://www.phenxtoolkit.org/), PhenX Social Determinants of Health Assessments Collection, NIDA Longitudinal Cohort studies of people with HIV and SUD, MWCCS (MACS/WIHS Combined Cohort Study), IeDEA (IeDEA International epidemiology Databases to Evaluate AIDS), NNTC (The National NeuroAIDS Tissue Consortium), CHARTER (CNS HIV Antiretroviral Therapy Effects Research Study).

National Cancer Institute (NCI)

The NCI seeks to eliminate cancer-related disparities by promoting and conducting health equity research that identifies and addresses the mechanisms contributing to disparities across the cancer control continuum and throughout the human lifespan. For this NOSI, the NCI is interested in the development, testing, implementation of interventions addressing gender-related health disparities on cancer prevention, diagnosis, and treatment outcomes. Studies are encouraged to use interoperable sexual orientation and gender identity (SOGI) data collection, such as the measures included in the National Academies of Sciences, Engineering, and Medicine (NASEM) report on SOGI data collection

Topics of particular interest include but are not limited to:

• The intersectionality of gender with other social variables (such as race, ethnicity, socioeconomic status, level of education, disability, sexual orientation, etc.) and/or structural variables (such as state and federal policies) and their effect on cancer incidence, diagnosis, treatment, and survival
• Structural discrimination studies that incorporate macro-level conditions to study the health impacts of gender-related variables
• Gender bias associated with diagnostic delays for cancer
• Understanding and/or addressing barriers to quality care delivery, including cancer treatment and follow-up care based on gender roles and gender inequity
• Development, implementation, and/or evaluation of multi-level interventions (e.g., at the individual, patient, provider, family, organizational, community and/or system levels) that are tested in collaboration with community partner(s) and address the impact of social and structural factors on cancer risk and/or outcomes
• Gendered influences on cancer prevention, treatment, and outcomes of cancers of the female reproductive system
• Community-led interventions to address gender-related cancer disparities
• Addressing gender-related cancer disparities related to HIV-associated malignancies

National Heart, Lung and Blood Institute (NHLBI)

The NHLBI is interested in supporting research relevant to our mission in the areas of heart, lung, blood and sleep disorders. Proposed research may include observational studies, epidemiological studies or clinical trials. NHLBI will support clinical trials that are mechanistic in nature and address either the social or structural domains of gender in the development, prevention or treatment of HBLS disorders/diseases, or mechanistic trials that examine the intersection of social and structural gender variables. NHLBI will not support non-mechanistic clinical trials.

Topics of particular interest to NHLBI include, but are not limited to:

• Studies investigating the role of gender in the mechanisms of HBLS disease/disorder development.
• Studies that leverage TOPMed data to examine the underlying social and structural influences on biological mechanisms of disease.
• Understanding gender in adherence to interventions for the treatment or prevention of HBLS diseases/disorders.
• The intersection between social and structural influences and gender on the impact of diseases/disorders.
• Understanding the influence of gender in the recognition, prevention, and treatment of pregnancy complications including preeclampsia, gestational diabetes, hypertension, peripartum cardiomyopathy, infection, and hemorrhage to address high rates of maternal morbidity and mortality and related health disparities in the U.S.
• Epidemiological studies that investigate social and structural gender-related variables on disparities in cardiovascular health outcomes.
• Implementation studies that test the effectiveness of interventions aimed at addressing social or structural gender domains to reduce gender health disparities.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

The NICHD mission is to lead research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all. The NICHD's broad and diverse research portfolio includes research related to conception and pregnancy; typical and atypical development in childhood; childhood trauma, injury, and critical illness; the transition from adolescence to adulthood; reproductive health; rehabilitation; intellectual, developmental, and physical disabilities; and population dynamics across the lifespan.

For this NOSI, NICHD seeks applications that investigate the influences of gender norms, roles, inequities, and/or power relations on the health of children, adolescents, or adults of reproductive ages and are aligned with NICHD’s scientific priorities as outlined in the NICHD Strategic Plan 2020.

Sexual & Gender Minority Research Office (SGMRO)

The SGMRO coordinates research and activities related to the health and well-being of sexual and gender minority (SGM; defined for NIH research in NOT-OD-19-139) populations by working directly with the NIH institutes, centers, and offices (ICOs) and serves as a liaison for the research community to ensure SGM populations are considered and represented in research activities across the agency. The SGMRO does not have grant-making authority and can only support grants deemed meritorious after review by one of the ICs participating in this announcement and after a co-funding request is initiated through the IC. Please reach out to the relevant Scientific/Research Contact(s) identified in this announcement with any questions about IC-specific research priorities and funding. More SGM- and SGMRO-specific information relevant to this opportunity is available in the NIH Strategic Plan to Advance Research on the Health and Well-being of Sexual and Gender Minorities FY 2021-2025 and on the Office’s Research Resources webpage.

For this NOSI, SGMRO encourages research across the life course that explores and addresses SGM-relevant and -specific issues related to gender and gender identity to support the maintenance or improvement of health and health outcomes among SGM communities and SGM people who are members of other populations that experience health disparities and inequities. When appropriate, SGMRO encourages consideration and incorporation of relevant concepts (e.g., minority stress, social safety, intersectionality, stigma), research strategies (e.g., community-led or -engaged research, trauma-informed research, strengths-based approaches), and frameworks (e.g., SGM Health Disparities Research Framework, NIMHD Research Framework).

Application and Submission Information

This NOSI applies to due dates on or after January 25, 2024, and subsequent receipt dates through September 30, 2025.

Submit applications for this initiative using one of the following notices of funding opportunites (NOFOs) or any reissues of these announcements through the expiration date of this notice.

Applicants must select the IC and associated NOFO to use for submission of an application in response to this NOSI. The selection must align with the IC requirements listed to be considered responsive to that NOFO. Non-responsive applications will be withdrawn from consideration for this initiative. In addition, applicants using NIH Parent Announcements (listed below) will be assigned to those ICs on this NOSI that have indicated those NOFOs are acceptable and based on usual application-IC assignment practices.

All instructions in the SF424 (R&R) Application Guide and the listed funding opportunity announcements must be followed, with the following additions:

• For funding consideration, applicants must include NOT-OD-24-038 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Inquiries

Please direct all inquiries to the contacts in Section VII of the listed notice of funding opportunity with the following additions/substitutions:

Scientific/Research Contact(s)

Elizabeth Anne Barr
Office of Research on Women’s Health (ORWH)
Telephone: 301-402-7895
Email: elizabeth.barr@nih.gov

Chipper Dean
National Cancer Institute (NCI)
Telephone: 240-276-7803
Email: chipper.dean@nih.gov

Teri Senn
National Institute of Mental Health (NIMH)
Telephone: 301-761-7852
Email: teri.senn@nih.gov

Ronna Popkin
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-827-5121
Email: ronna.popkin@mail.nih.gov

Keisher Highsmith
National Institute on Drug Abuse (NIDA)
Telephone: 301-402-1984
Email: keisher.highsmith@nih.gov

Ms. JoanaD arc C. Roe (HIV)
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-551-8908
Email: jroe@nih.gov

Eleanore Chuang (STIs)
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-747-7585
Email: eleanore.chuang@nih.gov

Marrah Lachowicz-Scroggins
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301.435.0222
E-mail: marrah.lachowicz-scroggins@nih.gov

Candice Price
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301- 435-7764
E-mail: candice.price@nih.gov

Corette Byrd
Office of AIDS Research (OAR)
Telephone: 301-761-7369
Email: corette.byrd@nih.gov

Cheryse A. Sankar
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-318-2889
Email: cheryse.sankar@nih.gov

Christopher Barnhart
Sexual and Gender Minority Research Office (SGMRO)
Telephone: 301-594-8983
Email: christopher.barnhart@nih.gov

Geetha Parthasarathy Bansal
FIC - FOGARTY INTERNATIONAL CENTER
Phone: (301) 496-1653
E-mail: geetha.bansal@nih.gov

Melissa Gerald, Ph.D.
National Institute on Aging (NIA)
Phone: 301-402-4156
E-mail: melissa.gerald@nih.gov

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).